fbpx
01 / 05
Infrastructure Upgrade to Kenya’s Vaccine Cold Chain Rolls Out

Gavi | Vaccination

Infrastructure Upgrade to Kenya’s Vaccine Cold Chain Rolls Out

“Kenya’s immunisation system has received a vital upgrade: 2,061 pieces of new and improved cold chain equipment – valued at US$ 7.09 million (1.1 billion Kenyan shillings) – will shore up preventive health care across the country’s 47 counties.

An unbroken cold chain – picture a network of fridges and cold boxes, spread across the entire planet – ensures that vaccines travel from manufacturer to destination, never dipping below or rising above their precariously narrow ideal temperature band. That permits the vaccines to remain potent – in other words, to save lives.”

From Gavi.

World Health Organization | Vaccination

Cross-Border Polio Vaccination Reaches 6.5 Million Children

“Between October 3 and 6, 2024, more than 6.5 million children were vaccinated in a successful synchronized polio campaign between Kenya and Uganda. This cross-border achievement began with a coordinated launch in Bungoma District, Kenya, and Mbale District, Uganda. 

Both countries have set an exemplary standard in their recent synchronized polio vaccination campaign conducted this week, which focused on high-risk cross-border regions. By conducting these campaigns on the same dates, sharing real-time information, both countries ensured that children under five in these vulnerable areas were reached effectively, reducing the chance of cross-border virus transmission.”

From World Health Organization.

The Guardian | Vaccination

Doctors Trial mRNA Vaccine Against Vomiting Bug Norovirus

“Doctors have begun trialling the world’s first mRNA vaccine against the vomiting bug norovirus in the hope the jab could bring huge health and economic benefits.

Norovirus causes sickness and diarrhoea and can spread very rapidly between people who are in close contact, with outbreaks often occurring in hospitals, care homes, schools and nurseries.

While most people recover within two to three days, the virus can be serious, particularly for the very young, elderly or people with a weakened immune system…

Called Nova 301, the phase 3 clinical trial is to run for two years, and will enrol 25,000 adults – with a focus on those over the age of 60 – from countries including Japan, Canada and Australia.”

From The Guardian.

STAT | Vaccination

FDA Approves First At-Home Flu Vaccine in US, a Nasal Spray

“The Food and Drug Administration on Friday approved AstraZeneca’s bid to allow its nasal spray influenza vaccine, FluMist, to be sold for home administration. 

Starting in fall 2025, people who want to order the vaccine to give it to themselves or their children at home will be able to do so. 

FluMist is the only flu vaccine administered by nasal spray, not injection. It is licensed for individuals between the ages of 2 and 49. This FDA approval makes it the only flu vaccine in the United States that can be administered at home and that does not need to be administered by a health care professional.”

From STAT.